EPIRUS Biopharmaceuticals Appoints J. Kevin Buchi to Board of Directors

  EPIRUS Biopharmaceuticals Appoints J. Kevin Buchi to Board of Directors

Business Wire

BOSTON -- June 27, 2013

EPIRUS Biopharmaceuticals, Inc. (EPIRUS), a privately held biotechnology
company focused on the development and production of biosimilar products in
and for major emerging markets, today announced the appointment of J. Kevin
Buchi to its Board of Directors.

“We are very pleased to have someone with Kevin’s experience and background
join our Board,” said Amit Munshi, CEO of EPIRUS. “His expertise and guidance
will be invaluable in our quest to build a world-class company.”

Mr. Buchi is the former Chief Executive Officer of Cephalon Inc., which was
sold to Teva Pharmaceutical Industries (Teva) in 2011. Mr. Buchi served as
Corporate Vice President, Global Branded Products for Teva from 2011 until his
retirement in 2012. Mr. Buchi joined Cephalon in 1991 and held various
positions, including Chief Operating Officer and Chief Financial Officer,
before becoming Cephalon’s CEO in December 2010. Mr. Buchi currently serves as
a member of the board of directors of Forward Pharma A/S, a privately held
biotechnology company in Copenhagen, Denmark. He also serves as a member of
the board of directors of Stemline Therapeutics (NASDAQ: STML), Alexza
Pharmaceuticals (NASDAQ: ALXA), and Benitec Biopharma (Australian Stock
Exchange: BLT).

Mr. Buchi graduated from Cornell University with a Bachelor of Arts degree in
chemistry and received a Master of Management degree from the J.L. Kellogg
Graduate School of Management at Northwestern University. He is a Certified
Public Accountant.

About EPIRUS Biopharmaceuticals

EPIRUS is focusing on the central development of a broad pipeline of
biosimilar monoclonal antibodies and therapeutic proteins, optimized for use
within the SCALE™ disposable manufacturing system, and designed to be deployed
in an “In Market, For Market” ™ manufacturing configuration.

SCALE is a modular state-of-the-art manufacturing process utilizing the latest
in disposable technology. It is ideally suited for use as a localized In
Market, For Market manufacturing solution designed to provide speed to market,
low capital cost, campaign flexibility and utilization rates which can be
tailored to local and or regional needs. This innovative product platform aims
to enable localized manufacturing in emerging economies where EPIRUS is
developing partnerships combining public and private sector financial support
and expertise. EPIRUS is focusing on a range of emerging markets, including,
Brazil, South Africa, Turkey, Russia, MENA, and the ASEAN markets.

EPIRUS envisions the creation of unprecedented patient access to biosimilar
therapeutics through efficient global development and local production of
these important medicines.

Contact:

EPIRUS Biopharmaceuticals, Inc.
Shannon Healey, 617-600-3497
shealey@epirusbiopharma.com
 
Press spacebar to pause and continue. Press esc to stop.